Table 2.
Subject characteristics for the women who were diagnosed with and undergoing chemotherapy treatment for breast cancer (BC).
| Characteristics | Frequency (%) |
|---|---|
| Cancer stage | |
| I | 4 (19) |
| II | 9 (43) |
| III | 4 (19) |
| Not identified/missing | 4 (19) |
| Menopause status | |
| Post-menopausal | 12 (57) |
| Pre-menopausal | 9 (43) |
| Chemotherapy drugs | |
| Included as part of total treatment regimen | |
| Doxorubicin | 8 |
| Capecitabine | 1 |
| Carboplatin | 10 |
| Cyclophosphamide | 10 |
| Docetaxel | 12 |
| Paclitaxel | 7 |
| Chemotherapy treatment combination/sequence | |
| Treatment received up to enrollment date | |
| Doxorubicin, cyclophosphamide | 2 (10) |
| Doxorubicin, cyclophosphamide, paclitaxel | 5 (23) |
| Doxorubicin, cyclophosphamide, paclitaxel, capecitabine | 1 (5) |
| Docetaxel, carboplatin, trastuzumab, pertuzumab | 8 (38) |
| Docetaxel, carboplatin, trastuzumab | 2 (10) |
| Docetaxel, cyclophosphamide | 2 (10) |
| Paclitaxel | 1 (5) |
| Mean time | Days (± SD) |
| Average time between most recent treatment and psychological questionnaires | 11.4 (11.3) |
| Range of time between most recent treatment and psychological questionnaires | 0–40 |
| Average time between most recent treatment and stool samples | 13 (14.4) |
| Range of time between most recent treatment and stool samples | 0–42 |
Data are displayed as n (%), mean days (± SD).